Literature DB >> 26241208

The NIH-Industry New Therapeutic Uses Pilot Program: Demonstrating the Power of Crowdsourcing.

Christine M Colvis1, Christopher P Austin1.   

Abstract

Mesh：

Year:  2015        PMID： 26241208      PMCID： PMC4533092          DOI： 10.1089/adt.2015.29006.cmcdrrr

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN： 1540-658X            Impact factor:   1.738


× No keyword cloud information.
  4 in total

1.  Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Authors:  Tara C Gangadhar; Joseph I Clark; Theodore Karrison; Thomas F Gajewski
Journal:  Invest New Drugs       Date:  2012-11-15       Impact factor: 3.850

2.  Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.

Authors:  J A P Spijkers-Hagelstein; S Mimoso Pinhanços; P Schneider; R Pieters; R W Stam
Journal:  Leukemia       Date:  2012-12-28       Impact factor: 11.528

3.  Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.

Authors:  Jane Kendrew; Rajesh Odedra; Armelle Logié; Paula J Taylor; Sharon Pearsall; Donald J Ogilvie; Stephen R Wedge; Juliane M Jürgensmeier
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-26       Impact factor: 3.333

4.  Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.

Authors:  John Arcaroli; Kevin Quackenbush; Arvind Dasari; Rebecca Powell; Martine McManus; Aik-Choon Tan; Nathan R Foster; Joel Picus; John Wright; Sujatha Nallapareddy; Charles Erlichman; Manuel Hidalgo; Wells A Messersmith
Journal:  Cancer Med       Date:  2012-08-16       Impact factor: 4.452
  4 in total
  4 in total

Review 1.  Pioneering government-sponsored drug repositioning collaborations: progress and learning.

Authors:  Donald E Frail; Madeleine Brady; K Jane Escott; Alison Holt; Hitesh J Sanganee; Menelas N Pangalos; Chris Watkins; Craig D Wegner
Journal:  Nat Rev Drug Discov       Date:  2015-11-20       Impact factor: 84.694

2.  The Rescue and Repurposing of Pharmaceuticals: Augmenting the Drug Development Paradigm.

Authors:  Michael D Reed
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

Review 3.  Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.

Authors:  Tonio Pera; Raymond B Penn
Journal:  Pharmacol Ther       Date:  2016-04-23       Impact factor: 12.310

Review 4.  Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.

Authors:  Erik Tambuyzer; Benjamin Vandendriessche; Christopher P Austin; Philip J Brooks; Kristina Larsson; Katherine I Miller Needleman; James Valentine; Kay Davies; Stephen C Groft; Robert Preti; Tudor I Oprea; Marco Prunotto
Journal:  Nat Rev Drug Discov       Date:  2019-12-13       Impact factor: 84.694
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.